These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

248 related items for PubMed ID: 29378355

  • 1. A Genome-wide Study of Common and Rare Genetic Variants Associated with Circulating Thrombin Activatable Fibrinolysis Inhibitor.
    Stanne TM, Olsson M, Lorentzen E, Pedersen A, Gummesson A, Gils A, Jood K, Engström G, Melander O, Declerck PJ, Jern C.
    Thromb Haemost; 2018 Feb; 118(2):298-308. PubMed ID: 29378355
    [Abstract] [Full Text] [Related]

  • 2. Effect of single nucleotide polymorphisms on expression of the gene encoding thrombin-activatable fibrinolysis inhibitor: a functional analysis.
    Boffa MB, Maret D, Hamill JD, Bastajian N, Crainich P, Jenny NS, Tang Z, Macy EM, Tracy RP, Franco RF, Nesheim ME, Koschinsky ML.
    Blood; 2008 Jan 01; 111(1):183-9. PubMed ID: 17855631
    [Abstract] [Full Text] [Related]

  • 3. A locus on chromosome 13 influences levels of TAFI antigen in healthy Mexican Americans.
    Warren DM, Cole SA, Dyer TD, Soria JM, Souto JC, Fontcuberta J, Blangero J, Maccluer JW, Almasy L.
    Hum Biol; 2006 Jun 01; 78(3):329-39. PubMed ID: 17216805
    [Abstract] [Full Text] [Related]

  • 4. Association of a single nucleotide polymorphism in CPB2 encoding the thrombin-activable fibrinolysis inhibitor (TAF1) with blood pressure.
    Koschinsky ML, Boffa MB, Nesheim ME, Zinman B, Hanley AJ, Harris SB, Cao H, Hegele RA.
    Clin Genet; 2001 Nov 01; 60(5):345-9. PubMed ID: 11903334
    [Abstract] [Full Text] [Related]

  • 5. Thrombin-activatable fibrinolysis inhibitor influences disease severity in humans and mice with pneumococcal meningitis.
    Mook-Kanamori BB, Valls Serón M, Geldhoff M, Havik SR, van der Ende A, Baas F, van der Poll T, Meijers JC, P Morgan B, Brouwer MC, van de Beek D.
    J Thromb Haemost; 2015 Nov 01; 13(11):2076-86. PubMed ID: 26340319
    [Abstract] [Full Text] [Related]

  • 6. Plasma thrombin-activatable fibrinolysis inhibitor antigen concentration and genotype in relation to myocardial infarction in the north and south of Europe.
    Juhan-Vague I, Morange PE, Aubert H, Henry M, Aillaud MF, Alessi MC, Samnegård A, Hawe E, Yudkin J, Margaglione M, Di Minno G, Hamsten A, Humphries SE, HIFMECH Study Group.
    Arterioscler Thromb Vasc Biol; 2002 May 01; 22(5):867-73. PubMed ID: 12006404
    [Abstract] [Full Text] [Related]

  • 7. A new pedigree with thrombomodulin-associated coagulopathy in which delayed fibrinolysis is partially attenuated by co-inherited TAFI deficiency.
    Westbury SK, Whyte CS, Stephens J, Downes K, Turro E, Claesen K, Mertens JC, Hendriks D, Latif AL, Leishman EJ, NIHR BioResourceNIHR BioResource, Cambridge University Hospitals, Cambridge, UK., Mutch NJ, Tait RC, Mumford AD.
    J Thromb Haemost; 2020 Sep 01; 18(9):2209-2214. PubMed ID: 32634856
    [Abstract] [Full Text] [Related]

  • 8. Thrombin activatable fibrinolysis inhibitor activation peptide shows association with all major subtypes of ischemic stroke and with TAFI gene variation.
    Ladenvall C, Gils A, Jood K, Blomstrand C, Declerck PJ, Jern C.
    Arterioscler Thromb Vasc Biol; 2007 Apr 01; 27(4):955-62. PubMed ID: 17272741
    [Abstract] [Full Text] [Related]

  • 9. Regulation of the gene encoding human thrombin-activatable fibrinolysis inhibitor by estrogen and progesterone.
    Garand M, Lin JH, Zagorac B, Koschinsky ML, Boffa MB.
    Blood Coagul Fibrinolysis; 2013 Jun 01; 24(4):393-404. PubMed ID: 23429253
    [Abstract] [Full Text] [Related]

  • 10. [Study on the association of thrombin activatable fibrinolysis inhibitor and the Thr325Ile and Thr147Ala polymorphisms of its encoding gene CPB2 in patients with coronary heart disease].
    Xu CW, Wang LL, Wu XB, Zhao JJ, Du YM, Jiang CY.
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2008 Aug 01; 25(4):438-42. PubMed ID: 18683146
    [Abstract] [Full Text] [Related]

  • 11. Thrombin-activatable fibrinolysis inhibitor in human abdominal aortic aneurysm disease.
    Bridge KI, Bollen L, Zhong J, Hesketh M, Macrae FL, Johnson A, Philippou H, Scott DJ, Gils A, Ariёns RAS.
    J Thromb Haemost; 2017 Nov 01; 15(11):2218-2225. PubMed ID: 28834317
    [Abstract] [Full Text] [Related]

  • 12. Nobiletin, a polymethoxyflavone in citrus fruits, reduces TAFI expression in HepG2 cells through transcriptional inhibition.
    Takada K, Seike T, Sasaki T, Masuda Y, Ito A, Ishii H.
    Thromb Haemost; 2013 Jun 01; 109(6):1060-9. PubMed ID: 23572161
    [Abstract] [Full Text] [Related]

  • 13. [Prognosis value of thrombin activatable fibrinolysis inhibitor concentration and C1040T polymorphism in acute myocardial infarction treated with fibrinolysis].
    González FJ, Caturla JM, Fernández M, Carrasco R, Marco P, Sánchez J, Benlloch S.
    Med Intensiva; 2010 Nov 01; 34(8):513-22. PubMed ID: 20627371
    [Abstract] [Full Text] [Related]

  • 14. PI3-Kinase Inhibitor LY294002 Repressed the Expression of Thrombin-Activatable Fibrinolysis Inhibitor in Human Hepatoma HepG2 Cells.
    Masuda Y, Yazawa J, Makino Y, Takada K.
    Biol Pharm Bull; 2015 Nov 01; 38(10):1529-35. PubMed ID: 26424017
    [Abstract] [Full Text] [Related]

  • 15. Identification of a thrombomodulin interaction site on thrombin-activatable fibrinolysis inhibitor that mediates accelerated activation by thrombin.
    Marar TT, Boffa MB.
    J Thromb Haemost; 2016 Apr 01; 14(4):772-83. PubMed ID: 26816270
    [Abstract] [Full Text] [Related]

  • 16. Activated thrombin activatable fibrinolysis inhibitor levels are associated with the risk of cardiovascular death in patients with coronary artery disease: the AtheroGene study.
    Tregouet DA, Schnabel R, Alessi MC, Godefroy T, Declerck PJ, Nicaud V, Munzel T, Bickel C, Rupprecht HJ, Lubos E, Zeller T, Juhan-Vague I, Blankenberg S, Tiret L, Morange PE, AtheroGene Investigators.
    J Thromb Haemost; 2009 Jan 01; 7(1):49-57. PubMed ID: 19017260
    [Abstract] [Full Text] [Related]

  • 17. Thrombin-activatable fibrinolysis inhibitor (TAFI) levels and its polymorphism rs3742264 are associated with dyslipidemia in a cohort of Brazilian subjects.
    Santos IR, Fernandes AP, Carvalho MG, Sousa MO, Ferreira CN, Gomes KB.
    Clin Chim Acta; 2014 Jun 10; 433():76-83. PubMed ID: 24631134
    [Abstract] [Full Text] [Related]

  • 18. Quantification of thrombin activatable fibrinolysis inhibitor (TAFI) gene polymorphism effects on plasma levels of TAFI measured with assays insensitive to isoform-dependent artefact.
    Frère C, Morange PE, Saut N, Tregouet DA, Grosley M, Beltran J, Juhan-Vague I, Alessi MC.
    Thromb Haemost; 2005 Aug 10; 94(2):373-9. PubMed ID: 16113828
    [Abstract] [Full Text] [Related]

  • 19. Thrombin-activatable fibrinolysis inhibitor is associated with severity and outcome of severe meningococcal infection in children.
    Emonts M, de Bruijne EL, Guimarães AH, Declerck PJ, Leebeek FW, de Maat MP, Rijken DC, Hazelzet JA, Gils A.
    J Thromb Haemost; 2008 Feb 10; 6(2):268-76. PubMed ID: 18021301
    [Abstract] [Full Text] [Related]

  • 20. Low thrombin activatable fibrinolysis inhibitor activity levels are associated with an increased risk of a first myocardial infarction in men.
    Meltzer ME, Doggen CJ, de Groot PG, Meijers JC, Rosendaal FR, Lisman T.
    Haematologica; 2009 Jun 10; 94(6):811-8. PubMed ID: 19377074
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.